Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company addressing serious diseases with significant unmet need, has signed a manufacturing collaboration agreement with Cook MyoSite, Inc. (Cook MyoSite) to facilitate Chemistry,...
Mankind Pharma, the creator of top-selling condom brand Manforce Condoms and funded by private equity firm ChrysCapital, has set the share price band for its initial public offering at Rs 1,026-1,080 per share, valuing the company at Rs 43,264....
Siemens Healthineers today opened a new manufacturing facility in Bengaluru for Magnetic Resonance Imaging machines. MAGNETOM Free.Star, a disruptively simple approach to high-quality MRI, will be manufactured in India at the moment....
Nigeria granted provisional approval to Oxford University's R21 malaria vaccine on Monday, becoming the second country to do so after Ghana last week. The approvals are unusual in that they came before the vaccine's final-stage trial data was...
ATMA Journey Centres Inc. (ATMA), Canada's leading psychedelic-assisted therapy training provider, announced that it has submitted to Health Canada a N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA), which...
Lord’s Mark Industries, a prominent diversified business group, has launched The Hygiene India platform to promote holistic hygiene and health culture throughout India. The platform's objective is to become the country's largest health and hygiene...
At the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 15 - 18 April 2023, AstraZeneca will highlight new data across its vaccines and immune therapies portfolio, reinforcing its ambition to provide long-lasting...
The corporation will pay $200 per share for Prometheus Biosciences through one of its subsidiaries. Merck & Co has agreed to buy Prometheus Biosciences Inc for roughly $10.8 billion to expand its immunological business, the firms announced...
As a component of the National Institutes of Health (NIH), the National Cancer Institute (NCI) has assisted in the beginning of a phase 3 randomised clinical trial (NCT05633602) evaluating a two-drug combination for the treatment of patients with...
The agreement between ProBioGen and ImmunOs Therapeutics has been extended in order to continue producing clinical materials on a wide scale for IOS-1002, ImmunOs' main initiative for the treatment of cancer. For the novel biologic created by...
, CDSCO.jpg)
